ArticleDiagnostics (Basel, Switzerland)2019
Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value.
Article in Diagnostics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Cardiac function and mechanics in systemic sclerosis: a systematic review and meta-analysis.Echo research and practice · 2025Review
- Long-term prognostic value of native myocardial tissue relaxation parameters (T1, T2, and T1ρ) in patients with precapillary pulmonary hypertension.The international journal of cardiovascular imaging · 2025Article
- Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study.Rheumatology (Oxford, England) · 2025Article
- The emerging role of cardiovascular magnetic resonance in the evaluation of cardiac involvement in systemic sclerosis.Rheumatology and immunology research · 2024Article
- Cardiac magnetic resonance imaging in systemic sclerosis: Heart involvement in high-resolution.Rheumatology and immunology research · 2024Article
- Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment.Journal of scleroderma and related disorders · 2023Review
- The clinical characteristics and outcomes of patients with systemic sclerosis with myocardial involvement.Orphanet journal of rare diseases · 2023Article
- Myocardial fibrosis and arrhythmic burden in systemic sclerosis.Rheumatology (Oxford, England) · 2022Article
- The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.International journal of molecular sciences · 2022Review
- T2 mapping in myocardial disease: a comprehensive review.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2022Review
- Cardiovascular Imaging for Systemic Sclerosis Monitoring and Management.Frontiers in cardiovascular medicine · 2022Review
- The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis.Frontiers in cardiovascular medicine · 2022Article
- Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.Frontiers in immunology · 2022Review
- Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases.Diagnostics (Basel, Switzerland) · 2021Article
- CHLD score, a new score based on traditional risk factor evaluation and long-term cardiovascular outcomes in patients with systemic sclerosis.Scientific reports · 2021Article
- Sudden Cardiac Death in Systemic Sclerosis: Diagnostics to Assess Risk and Inform Management.Diagnostics (Basel, Switzerland) · 2021Review
- Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis.World journal of cardiology · 2021Article
- Ventricular Tachycardia Has Mainly Non-Ischaemic Substrates in Patients with Autoimmune Rheumatic Diseases and a Preserved Ejection Fraction.Diagnostics (Basel, Switzerland) · 2021Article
- Cardiovascular Magnetic Resonance Reveals Cardiac Pathophysiology in Autoimmune Rheumatic Diseases.Mediterranean journal of rheumatology · 2021Review
- Imaging in Diagnosis of Systemic Sclerosis.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute cardiac events are a significant contributor to mortality in systemic sclerosis (SSc). However, echocardiographic evaluation may be deceptively normal during an acute presentation. We hypothesized that in diffuse SSc patients presenting with acute cardiac events and a normal echocardiogram, cardiovascular magnetic resonance (CMR) would have incremental diagnostic/prognostic value.
methods50 consecutive diffuse SSc patients with normal echocardiograms were evaluated using a 1.5T system. A total of 27 (63%) had experienced an acute cardiac event three to tendays before CMR evaluation (rhythm disturbances, angina pectoris, shortness of breath). Left/right ventricular (LV/RV) volumes and ejection fractions (EF), as well as LV mass, the T2-signal ratio, early/late gadolinium enhancement (EGE/LGE), native/post-contrast T1-mapping, T2-mapping and extracellular volume fraction (ECV) were compared between the event and no-event groups.
resultsNo differences were identified in LV/RV volumes/EF/mass. In logistic regression analyses, independent predictors of belonging to the event group were EGE (odds ratio (95% CI): 1.55 (1.06-2.26),
conclusionsA normal echocardiogram does not preclude myocardial lesions in diffuse SSc patients, which can be detected by CMR especially in symptomatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.